Von Willebrand Disease Treatment Market is segmented By Disease Type (Type 1 vWD, Type 2 vWD, Type 3 vWD, Acquired vWD), By Drug Type (Clot-stabilizing Medications, Desmopressin, Contraceptives, Replacement Therapies, Fibrin Sealants, Others), By Route of Administration (Oral, Injection, Others), By Gender (Men, Women), By Distribution Channel (Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Von Willebrand Disease Treatment Market Size
Von Willebrand Disease Treatment Market size was valued US$ 304.9 million in 2022 and is estimated to reach US$ 728.1 million by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031). Von Willebrand disease (vWD) is a common genetic hemorrhagic disorder caused by a deficiency or dysfunction of the protein termed von Willebrand factor (vWF).
VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. There are many treatment options available for patients with von Willebrand disease including hormonal and non-hormonal therapies.
Von Willebrand Disease Treatment Market Scope
|
Metrics |
Details |
|
Market CAGR |
6.5% |
|
Segments Covered |
By Type, By Disease, By Drug Type, By Route of Administration, By Gender, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Von Willebrand Disease Treatment Market Dynamics
The major driving forces are the rising prevalence of von Willebrand disease globally, increasing patient assistance programs and increasing awareness about this disease are some of the key factors.
Increasing prevalence of von Willebrand disease and rising awareness are expected to drive market growth.
The von Willebrand disease (VWD) treatment market is growing due to rising prevalence of von Willebrand disease globally. In 2019, the PWD is estimated to affect approximately 1% of the general population, however, clinically significant disease prevalence is estimated to be about 125 per million, with severe disease affecting up to five per million. This disease has an equal distribution among males and females. The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For instance, it has been reported up to 20% of malignancies, and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. According to the World Federation of Hemophilia’s annual global survey, which is conducted every year, in 2019, 76,144 people were affected by von Willebrand disease (vWD) worldwide.
In addition, rising awareness towards von Willebrand disease (VWD) and increasing patient assistance programs are also driving the growth of the market. Von Willebrand disease (VWD) is a rare hereditary which may not be diagnosed and requires awareness in patient assistance programs. Several organizations and companies are focusing on increasing awareness among people about von Willebrand disease. For instance, the American Society of Hematology (ASH) takes several initiatives such as the establishment of the clinical research training institute in Latin America, implementation of global research award and visitor training program which are expected to boost the growth of the market during the forecast period.
High cost associated with treatment is expected to hamper the market growth.
The high cost of treatment is one of the major challenges for patients with von Willebrand disease (VWD). The cost of investments for drug development is high as due to the rarity and distinctive treatment approach for this disease. The drugs for von Willebrand disease treatment are synthetic in nature, and the cost of recombinant therapy is higher. Hence, high cost is one of the major factors hindering the growth of the market.
Industry Analysis
The global von Willebrand disease treatment market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, epidemiology, supply chain analysis, pipeline analysis, pricing analysis, product innovations and unmet needs.
Von Willebrand Disease Treatment Market Segment Analysis
Type 1 von Willebrand disease segment is expected to hold the largest market share in global von Willebrand disease treatment market
On the basis of disease type, the von Willebrand disease (vWD) treatment market is segmented into Type 1 vWD, Type 2 vWD, Type 3 vWD, and acquired vWD. Among these, the type 1 von Willebrand disease segment accounted for the largest market share, owing to the increasing number of Type 1 vWD cases and new product development. The increase in the patient pool for Type 1 vWD accounts for 60% to 80% of the patients with vWD which drives the growth of this segment. A person with Type 1 vWD also might have low levels of factor VIII, another type of blood-clotting protein. About 85% of people treated for VWD have Type 1. The Type 1 von Willebrand disease is treated by desmopressin, a synthetic hormone that allows the Von Willebrand factor in the blood vessels lining to be released. Type 1 and Type 2 of Von Willebrand disease have more effective results with this type of Willebrand Disease treatment as compared to the other types.
Based on drug type, the global von Willebrand disease (vWD) treatment market is segmented into clot-stabilizing medications, desmopressin, contraceptives, replacement therapies, fibrin sealants, and others. Among these, the desmopressin segment held the major share, owing to better effectiveness in the treatment of the disease compared to others. Desmopressin acetate Injection (DDAVP), is a medicine that is injected into a vein to treat people with milder forms of VWD (mainly type 1). It works by making the body release more VWF into the blood. It helps increase the level of factor VIII in the blood as well.
If desmopressin is not effective then the von Willebrand disease (vWD) is treated with replacement therapies. Several other therapies are being introduced which reduce the risk of allergic conditions or viral infection. For women facing heavy menstrual flow, contraceptives are provided as a treatment option. Other clot-stabilizing drugs help mainly in dental procedures by slowing down the breakdown of blood clots.
Von Willebrand Disease Treatment Market Geographical Share
North America region holds the largest market share in the global von Willebrand disease treatment market
North America is dominating the global von Willebrand disease treatment market accounting for the largest market share, owing to the rising prevalence of von Willebrand disease (vWD), increase in patient assistance programs, and the introduction of gene therapy. VWD is the most common bleeding disorder, found in up to 1% of the U.S. population, i.e., 3.2 million (or about 1 in every 100) people in the United States have the disease. In this region, the healthcare sector continues to evolve and positive growth has been observed in drug discovery and development.
In addition, rising technological advancements are driving the drug development in terms of von Willebrand disease treatment to offer better disease management to patients.
Several organizations, key players are adopting various strategies such as mergers, collaborations, product launches to generate awareness and develop clinical practices on the diagnosis and treatment of the disease. For instance, In Feb 2020, Novo Nordisk launched ESPEROCT a recombinant factor VIII product that is used for treating bleeding frequency in patients with hemophilia A.
The Asia-Pacific von Willebrand disease treatment market is expected to growth at a significant CAGR during the forecast period, owing to rising cases of von Willebrand disease, increasing initiatives by governments for healthcare access in developing countries. According to Hemophilia Federation India 2019 report, there were about 20,727 people with Hemophilia in India (2018) of which 81% is Hemophilia A, 12% is Hemophilia B and about 3% is attributable to von Willebrand disease (VWD).
In May 2019, the Indian Council of Medical Research (ICMR) has developed an affordable test kit for the diagnosis of common blood disorders such as severe Haemophilia A and von Willebrand disease (VWD). According to the ICMR scientists, the diagnosis can be done within 30 minutes of blood sample collection.
Von Willebrand Disease Treatment Companies and Competitive Landscape
The Von Willebrand Disease Treatment market is highly competitive with the presence of a large number of players including Grifols, S.A., Octapharma AG, Baxter, Shire plc, Bayer AG, Novo Nordisk A/S, Pfizer, CSL Behring, Sanofi, and Ferring B.V.
The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Von Willebrand Disease Treatment market globally. For instance,
- In Apr 2022, Octapharma completed its phase III trial in von Willebrand disease in USA, Russia, Ukraine, Bulgaria, Hungary in adults, adolescents and children.
- In Jan 2022, Takeda Pharmaceuticals announced the approval of VONVENDI by U.S. Food and Drug Administration. It is the only recombinant von Willebrand factor replacement therapy to minimize the bleeding frequency in severe Type 3 von Willebrand disease patients.
- In Feb 2020, Novo Nordisk launched ESPEROCT a recombinant factor VIII product that is used for treating bleeding frequency in patients with hemophilia A.
- In Jan 2019, Shire plc got acquired by Takeda Pharmaceutical Company Limited. Now they will focus on its major therapeutic areas that are Oncology. Neuroscience, GI, Plasma derived therapies and rare diseases.
Global Von Willebrand Disease Treatment Market – Key Companies to Watch
Grifols S.A.:
Overview: Grifols is multinational pharmaceutical company that manufactures chemicals as well. It is a major producer of blood plasma-based products and also provides clinical testing labs with instruments, devices and reagents. It was founded in 1940 and is headquartered in Barcelona, Spain.
Product Portfolio:
ALPHANATE: It is a human plasma-derived von Willebrand factor or factor VIII product that treats patients suffering from von Willebrand disease and hemophilia A.
Key Developments: In Apr 2022, Grifols plasma derived medicine producer announced its acquisition of Tiancheng Pharmaceutical a German company that holds Biotest shares. Biotest AG will help Grifols in expanding its products portfolio and enhances plasma therapies availability for patients.
The global von Willebrand disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
